tbuckley/cabot-search huggingface dataset:
Results of a Prospective Study Comparing Whole-Body Diffusion-Weighted Magnetic Resonance Imaging with Skeletal X-Ray and Magnetic Resonance of the Spine for Assessing Bone Disease in Multiple Myeloma.
Authors: Francesco Spina, Paolo Potepan, Giovanna Trecate, Eros Montin, Vittorio Montefusco, Alberto Laffranchi, Luca Mainardi, Pietro Panizza, Luigi Mariani, Paolo Corradini
Journal: Blood (2012)
Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)
Authors: Sarit Assouline, Valeria Buccheri, Alain Delmer, Gianluca Gaidano, Michael Brewster, Olivier Catalani, Sai Li, Christine McIntyre, Pakeeza Sayyed, Xavier C Badoux
Journal: Blood (2014)
Hyperfibrinolysis and Point-of-Care Thromboelastography: Rapid Detection of Hyperfibrinolysis without Immediate Antifibrinolysis Confers Worse Survival Results Than Prophylaxis, In Liver Transplantation
Authors: Marta I Pereira, Gilberto P Marques, Carlos Bento, Maria Leticia Ribeiro
Journal: Blood (2010)
Adjuvant weekly “AC+G” followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up
Authors: G. K. Ellis, T. Thompson, H. M. Linden, K. Rinn, A. E. Murphy, J. R. Gralow, R. B. Livingston
Journal: Journal of Clinical Oncology (2005)

628 We have previously reported DFS for the adjuvant treatment of node-positive breast cancer with a median of 4 involved nodes of 86% at 5 years using a 20–24 week regimen of weekly doxorubicin (20–24 mg/m2), daily oral cyclophosphamide (60 mg/m2) ± weekly 5FU (300 mg/m2) and scheduled filgrastim support (5 mcg/kg/day, days 2–7) (“ AC+G,” Ellis G et al JCO 2002 20(17): 3637–3643). We report now on 54 patients treated on a Seattle Cancer Care Alliance/University of Washington successor study with 12 weeks of AC+G followed by 12 weeks of weekly paclitaxel (80 mg/m2). Median age was 50. Median number of involved nodes was 5, with 33% having 1–3, 39% with 4–9, and 28% > 10 involved nodes 41/54 patients had either 4 or more involved nodes, OR ER/PR negative disease OR HER-2/neu positive disease (3+ by IHC, or FISH+). Eighty percent had ER positive disease, 22% had HER-2/neu positive disease. Grade 3–4 toxicities, for the “ AC+G” or paclitaxel portion of treatment, were as follows, respectively: neutropenia 11%, 23% febrile neutropenia 0%, 2% mucositis 6%, 0% hand-foot syndrome 7%, 0% RBC transfusion 4%, 2% nausea, vomiting 2%, 0%. Additional hormonal therapy was administered for patients with ER or PR positive disease: tamoxifen in 31%, tamoxifen followed by an aromatase inhibitor, 13% aromatase inhibitor 31% aromatase inhibitor followed by tamoxifen 2%. Disease-free survival at 3 years is 90% compared to 86% in the previous study, (F)AC+G. By way of further comparison, Citron et al reported a DFS of 82% at 4 years for CALGB 9741 for patients with a median of 3 positive nodes. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen, Bristol-Myers Squibb Amgen, Bristol-Myers-Squibb
SURG-15PROGRESSIVE T2/FLAIR SIGNAL CHANGE AFTER RESECTION OF LOW-GRADE GLIOMA – WHAT DOES IT SIGNIFY?
Authors: John Goodden, Suzanne Spink, Tufail Patankar, Jeremy MacMullen-Price, Daniel O'Hara, Melissa Maguire, Carmel Loughrey, Aruna Chakrabarty, Paul Chumas
Journal: Neuro-Oncology (2015)

BACKGROUND: Several international series' have demonstrated the importance of extensive resection in controlling Low Grade Glioma (LGG).After surgery, regular MRI monitoring is undertaken for evidence of recurrence.Since LGG are typically demonstrated as hyperintense signal on T2 and FLAIR MRI scans, an increase in T2/FLAIR signal around the resection Overall survival
Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection
Authors: Amanda Cashen, Michael P. Rettig, Feng Gao, Camille N. Abboud, Keith E. Stockerl-Goldstein, Ravi Vij, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio
Journal: Blood (2010)
Multicenter phase II study of docetaxel and oxaliplatin combination in patients with locally advanced or metastatic biliary tract cancer.
Authors: Eun-Kee Song, Hye-Suk Han, Ki Hyeong Lee, Kyu Taek Lee, Sang Byung Bae, Han Jo Kim, Samyong Kim, Hwan Jung Yun, Sang Hee Cho, Hyun-Jeong Shim, Ho-Young Yhim, Na-Ri Lee, So Yeon Jeon, Chang-Yeol Yim
Journal: Journal of Clinical Oncology (2014)

e15150 Background: Patients with biliary tract cancer have a poor prognosis and the palliative chemotherapy has shown limited efficacy. This phase II study aimed to evaluate the efficacy and safety of a combination of docetaxel and oxaliplatin as first-line therapy in patients with advanced biliary tract cancer. Methods: From Jul. 2010 to Jun. 2012, patients with unresectable locally advanced or metastatic biliary tract cancer were enrolled and treated at five cancer centers in South Korea. All patients received docetaxel 35 mg/m(2) on days 1 and 8 and oxaliplatin 100 mg/m(2) on day 1, every 3 weeks. The primary outcome was overall response rate (ORR) and the secondary outcomes were treatment-related toxicities, progression free survival (PFS), and overall survival (OS). Analysis was conducted by an intention-to-treat basis. Response evaluation was done by RECIST criteria (version 1.1) and adverse reactions were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). The study is registered with ClinicalTrials.gov, number NCT01234051. Results: 19 patients (2 patients had locally advanced disease and 17 had metastatic disease) with median age of 58 years (range 45-74) were enrolled. Response was assessable in 17 patients (early death in two). ORR was 4/17 (23.5%; 95% CI, 3.3-43.7%) and disease control rate (PR + SD) was 12/17 (70.6%; 95% CI, 50.1-91.1%). At a median follow-up time of 35.3 months (range 2.3-37.8), median PFS for all patients was 2.8 months (95% CI, 0.8-4.8 months) and median OS was 10.0 months (95% CI, 2.1-17.9 months). The most common grade 3 or 4 hematologic and nonhematologic toxicities were neutropenia (42.1%) and peripheral neuropathy (10.5%), respectively. Conclusions: Docetaxel and oxaliplatin combination was moderately active and feasible in patients with locally advanced or metastatic biliary tract cancer. This regimen warrants further investigation as a first- or second-line therapy for the treatment of unresectable biliary tract cancer. Clinical trial information: NCT01234051.
Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy.
Authors: Irene M. Ghobrial, Alexey A. Leontocich, Jeanette E. Eckel, Michael Timm, Steve Ziesmer, Antje Hoering, Miguel Cabanela, Alex Nehme, Philip R. Greipp, Rafael Fonseca, Morie A. Gertz, Thomas E. Witzig
Journal: Blood (2004)
AKN-028, a FLT-3 Kinase Inhibitor In Preclinical Development, Induces Significant Gene Regulation That Differs From PKC-412
Authors: Vendela C Parrow, Anna Eriksson, Hanna Göransson, Linda Rickardson, Fredrik Lehmann, Lena Lenhammar, Rolf Larsson, Martin Hoglund
Journal: Blood (2010)
Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)
Authors: Marcus M Schittenhelm, Figen Akmut, Barbara Illing, Julia Frey, Katja Schuster, Abhijit Ramachandran, Lothar Kanz, Kerstin M Kampa-Schittenhelm
Journal: Blood (2014)
How much is too much alcohol in tuberculosis?
Authors: João Francisco, Olena Oliveira, Óscar Felgueiras, A. Rita Gaio, Raquel Duarte
Journal: European Respiratory Journal (2016)

About one-third of the population worldwide have Mycobacterium tuberculosis infections, although 90% of infected individuals never develop clinical disease [1, 2]. Heavy alcohol intake seems to increase risk of TB in males. New measures for alcohol abuse are needed <http://ow.ly/2Esr304cDg4> The author's contributions are as follows. Conception and design: R. Duarte and O. Oliveira; analysis and interpretation: J. Francisco, O. Felgueiras, A.R. Gaio and R. Duarte; drafting the manuscript for important intellectual content: J. Francisco, O. Oliveira, A.R. Gaio and R. Duarte.
Overcoming Resistance to Apoptosis in Multiple Myeloma By Simultaneous Inhibition of Bcl2 and IAP Families of Anti-Apoptotic Proteins
Authors: Marcus Gomez, Vijay G. Ramakrishnan, Vivek Prasad, Teresa K. Kimlinger, Utkarsh Painuly, Lintao Bi, Vincent Rajkumar, Shaji Kumar
Journal: Blood (2014)
Nonviral jet-injection gene transfer in patients with in-transit metastases from melanoma and cutaneous metastases from breast cancer: results of a Phase I clinical trial
Authors: Wolfgang Walther, Robert Siegel, Dennis Kobelt, Jutta Aumann, Ulrike Stein, Peter Schlag
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

1396 

Nonviral gene transfer is of growing importance in experimental as well as in clinical approaches. Particularly for transfer of naked DNA various physical transfer technologies, such as jet-injection, ballistic transfer, in vivo electroporation, sonoporation etc. have been developed. The needleless jet-injection technology is based on high-speed jets, which can penetrate deeper tissues leading to efficient gene transfer of naked DNA. We conducted a phase I clinical trial to apply the pCMVbeta beta-galactosidase (LacZ) expressing reporter-plasmid by intratumoral jet-injection to evaluate safety, feasibility and efficacy of nonviral gene transfer. We used the low-volume jet-injector prototype to apply the GMP-grade plasmid-DNA. In this clinical trial seventeen patients with in-transit metastases from melanoma or skin metastases from breast cancer were treated. All patients received five jet-injections of 0.01 mL plasmid-DNA (1mg/mL) into one single metastatic lesion. Two to six days post application tumor lesions were surgically removed for analyses. Throughout the study clinical and laboratory monitoring was performed. Tumor plasmid-load was determined by real-time PCR (qPCR) and LacZ-mRNA expression was analyzed by real-time RT-PCR. LacZ-protein expression and distribution was assessed by X-Gal-staining and Western-blot. Plasmid-clearance in the blood was analyzed by qPCR 0.5, 3, 6, 24, 48, 72 hours and 4 weeks after jet-injection. All seventeen patients tolerated the treatment well. Apart from minor bleeding at the injection sites, no adverse events or complications were observed. Within all tumors plasmid-DNA and LacZ-expression at mRNA- and protein-level was detected. Intratumoral plasmid-DNA load correlated well with LacZ-expression at mRNA- and protein-level. The qPCR-analysis of patient-blood revealed short, low-level peaking of plasmid-DNA 30 min. after jet-injection followed by rapid decline and clearance. The results from this phase I trial clearly demonstrate safety and feasibility of nonviral jet-injection gene transfer. A new phase-I/II-trial for therapeutic application of the jet-injection gene transfer will be initiated.
A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.
Authors: Noemi Horvath, Douglas E. Joshua, John Gibson, Andrew W. Roberts, John Norman, Craig Underhill, David M. Ross, Sonya Stephens, Trevor Rawling, Luen B. To
Journal: Blood (2005)
Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients
Authors: Dominique Farge, Lucas C. M. Arruda, Fanny Brigant, Emmanuel Clave, Corinne Douay, Zora Marjanovic, Christophe Deligny, Guitta Maki, Eliane Gluckman, Antoine Toubert, Helene Moins-Teisserenc
Journal: Journal of Hematology & Oncology (2017)

The determinants of clinical responses after autologous hematopoietic stem cell transplantation (aHSCT) in systemic sclerosis (SSc) are still unraveled. We analyzed long-term immune reconstitution (IR) and T cell receptor (TCR) repertoire diversity in 10 SSc patients, with at least 6 years simultaneous clinical and immunological follow-up after aHSCT. Patients were retrospectively classified as long-term responders (A, n = 5) or non-responders (B, n = 5), using modified Rodnan’s skin score (mRSS) and forced vital capacity (FVC%). All patients had similar severe SSc before aHSCT. Number of reinjected CD34+ cells was higher in group B versus A (P = 0.02). Long-term mRSS fall >25% was more pronounced in group A (P = 0.004), the only to improve long-term FVC% >10% (P = 0.026). There was an overall trend toward increased of T cell reconstitution in group B versus A. B cells had a positive linear regression slope in group A (LRS = 11.1) and negative in group B (LRS = −11.6). TCR repertoire was disturbed before aHSCT and the percentage of polyclonal families significantly increased at long-term (P = 0.046), with no difference between groups. Despite improved skin score after aHSCT in all SSc patients, pretransplant B cell clonal expansion and faster post-transplant T cell IR in long-term non-responder/relapsing patients call for new therapeutic protocols guided by IR analysis to improve their outcome.
Salvage Allogeneic Hematopoietic Cell Transplantation for Relapsed or Progressive Multiple Myeloma After Autologous Hematopoietic Cell Transplantation
Authors: Dominik Schneidawind, Katharina Oehrlein, Katja C Weisel, Christoph Faul, Lothar Kanz, Wolfgang A Bethge
Journal: Blood (2012)
Regulation of c-Myc Expression through the Depletion of THAP11 and Fbw7 by Bcr-Abl Promotes CML Cell Proliferation
Authors: Daisuke Yokota, Satoki Nakamura, Tomonari Takemura, Yasuyuki Nagata, Isao Hirano, Takaaki Ono, Kazuyuki Shigeno, Shinya Fujisawa, Kazunori Ohnishi
Journal: Blood (2010)
Decreased Heart Rate Variability in Patients With Diabetes Mellitus and Ischemic Heart Disease
Authors: Yukihiro Fujimoto, Masaharu Fukuki, Akira Hoshio, Norihito Sasaki, Toshihiro Hamada, Yasushi Tanaka, Akio Yoshida, Chiaki Shigemasa, Hiroto Mashiba
Journal: Circulation (1996)

We investigated the characteristics of decreased heart rate variability (HRV) in diabetic patients with ischemic heart disease (IHD). Twenty-one healthy control subjects, 17 diabetic patients without IHD, and 33 diabetic patients with IHD were studied. The diabetic patients with IHD were subdivided into 2 groups according to the severity of their IHD: severe or mild. HRV was evaluated in all subjects using the spectral variables of the all-frequency, Iow-requency, high-frequency (AF, LF, HF) components and the LF/HF ratio were determined from Holter recordings. The AF and LF components in patients with diabetes only or diabetes and severe IHD were significantly lower than in control group, but the HF component was significantly lower only in the group of patients with diabetes and severe IHD. The LF/HF ratio did not differ significantly among the 4 groups, but was the lowest in diabetic patients without IHD. Patients with diabetes and mild IHD showed a slight decrease in HRV, but this was not significant. With regard to the circadian rhythm of HRV, the AF and LF components in patients with diabetes-only or diabetes and severe IHD were significantly decreased and showed the same pattern throughout the day. However, the HF component was decreased during more time zones in patients with diabetes and severe IHD, whereas the LF/HF ratio was lower during more time zones in the diabetes-only group. All spectral variables showed a tendency to be inversely related to the duration of diabetes in all diabetic patients. In particular, the LF/HF ratio showed a significant negative correlation. The HRV of diabetic patients was characterized by a decreased LF/HF ratio. It was concluded that, although HRV in diabetic patients with severe IHD was reduced mainly as a result of diabetic neuropathy, this was also partly due to a decline in parasympathetic tone as a result of myocardial injury. (Jpn Circ J 1996; 60: 925 - 932)
Clusterin Expression and Localization Are Affected by Rituximab and Doxorubicin Treatment in Non-Hodgkin Lymphoma Cells and B Lymphocytes
Authors: Mariangela Coletta, Raffaele Frazzi, Federica Rizzi, Saverio Bettuzzi, Daniela Lasagni, Roberto Baricchi, Bruno Casali, Francesco Merli
Journal: Blood (2012)
Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial
Authors: S. Verelst, F. Termorshuizen, C. Uyl-de Groot, M. R Schaafsma, R. Ammerlaan, S. Wittebol, H. Sinnige, S. Zweegman, M. van Marwijk Kooy, R. van der Griend, H. Lokhorst, P. Sonneveld, P. Wijermans
Journal: Blood (2010)
Effect of Incentive Spirometry on Postoperative Hypoxemia and Pulmonary Complications After Bariatric Surgery
Authors: Haddon Pantel, John Hwang, David Brams, Thomas Schnelldorfer, Dmitry Nepomnayshy
Journal: JAMA Surgery (2017)

<h3>Importance</h3> The combination of obesity and foregut surgery puts patients undergoing bariatric surgery at high risk for postoperative pulmonary complications. Postoperative incentive spirometry (IS) is a ubiquitous practice; however, little evidence exists on its effectiveness. <h3>Objective</h3> To determine the effect of postoperative IS on hypoxemia, arterial oxygen saturation (Sao<sub>2</sub>) level, and pulmonary complications after bariatric surgery. <h3>Design, Setting, and Participants</h3> A randomized noninferiority clinical trial enrolled patients undergoing bariatric surgery from May 1, 2015, to June 30, 2016. Patients were randomized to postoperative IS (control group) or clinical observation (test group) at a single-center tertiary referral teaching hospital. Analysis was based on the evaluable population. <h3>Interventions</h3> The controls received the standard of care with IS use 10 times every hour while awake. The test group did not receive an IS device or these orders. <h3>Main Outcomes and Measures</h3> The primary outcome was frequency of hypoxemia, defined as an Sao<sub>2</sub>level of less than 92% without supplementation at 6, 12, and 24 postoperative hours. Secondary outcomes were Sao<sub>2</sub>levels at these times and the rate of 30-day postoperative pulmonary complications. <h3>Results</h3> A total of 224 patients (50 men [22.3%] and 174 women [77.7%]; mean [SD] age, 45.6 [11.8] years) were enrolled, and 112 were randomized for each group. Baseline characteristics of the groups were similar. No significant differences in frequency of postoperative hypoxemia between the control and test groups were found at 6 (11.9% vs 10.4%;<i>P</i> = .72), 12 (5.4% vs 8.2%;<i>P</i> = .40), or 24 (3.7% vs 4.6%;<i>P</i> = .73) postoperative hours. No significant differences were observed in mean (SD) Sao<sub>2</sub>level between the control and test groups at 6 (94.9% [3.2%] vs 94.9% [2.9%];<i>P</i> = .99), 12 (95.4% [2.2%] vs 95.1% [2.5%];<i>P</i> = .40), or 24 (95.7% [2.4%] vs 95.6% [2.4%];<i>P</i> = .69) postoperative hours. Rates of 30-day postoperative pulmonary complications did not differ between groups (8 patients [7.1%] in the control group vs 4 [3.6%] in the test group;<i>P</i> = .24). <h3>Conclusions and Relevance</h3> Postoperative IS did not demonstrate any effect on postoperative hypoxemia, Sao<sub>2</sub>level, or postoperative pulmonary complications. Based on these findings, the routine use of IS is not recommended after bariatric surgery in its current implementation. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT02431455
Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)
Authors: Julie M Vose, Shelly L Carter, Linda J Burns, Ernesto Ayala, Oliver W. Press, Craig H. Moskowitz, Edward A. Stadtmauer, Shin Mineishi, Richard F. Ambinder, Timothy S. Fenske, Mary M. Horowitz, Marcie Tomblyn
Journal: Blood (2011)
Promoter Shuffling by Sequential Genomic Rearrangements in Follicular Lymphoma Reveals an Ongoing Genomic Instability at the BCL6 Locus.
Authors: Philippe Ruminy, Fabrice Jardin, Jean Michel Picquenot, Dominique Penther, Francoise Parmentier, Herve Tilly, Christian Bastard
Journal: Blood (2006)
The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.
Authors: Catherine Veeder, Sheila Davies, Christina Havey, John J. Maciejewski, Sunita Nathan, Stephanie A. Gregory, Parameswaran Venugopal, Jamile Shammo, Henry C. Fung
Journal: Blood (2009)
Swirl Sign — Intestinal Volvulus after Roux-en-Y Gastric Bypass
Authors: Joseph Fernandez-Moure, Vadim Sherman
Journal: New England Journal of Medicine (2017)

A 56-year-old man who had undergone gastric bypass 7 years earlier presented with midabdominal pain, nausea, and bilious emesis. Swirling of the bowel and mesenteric vessels, shown in a video, was noted on CT.
Adoptively Transferred Mature T Cells Exhibit Diminished Reactivity to Murine Cytomegalovirus Compared to Nascent Donor T Cells and Impair Functional Immune Recovery After Allogeneic Hematopoietic Cell Transplantation.
Authors: Antonia MS Mueller, Sumana Shashidhar, Janice Brown, Judith A Shizuru
Journal: Blood (2010)
Detection and Production of Haptoglobin within Acute Myeloid Leukemic Blasts.
Authors: Daniel Lingamfelter, Na Yu, Tim Quinn, Casey Williams, Xiuqin Guan, Joseph McGuirk, Yayan Chen, Stella Abhyyankar, Navanshu Arora, Rakesh Gaur, Jeffery Wiemen, Ying Yan
Journal: Blood (2007)
Comparative Analysis of Single-Institute Transplantation From Unrelated Cord Blood and Related Adult Donors In Adults with Hematologic Malignancies.
Authors: Zimin Sun, Huilan Liu, Liangquan Geng, Xingbing Wang, Kaiyang Ding, Chengyang Zhou, Baolin Tang, Juan Tong, Wen Yao, Zuyi Wang
Journal: Blood (2010)
Risk Factors for Acute Graft-Versus-Host Disease After Related Hematopoietic Cell Transplantation in Children with Acute Leukemia
Authors: Mouhab F Ayas, Khawar Siddiqui, Amal Al-Seraihy, Abdallah Al-Jefri, Ashraf Khairi, Mohamed Al-Hinai, Ali Al-Ahmari, Asim F Belgaumi, Hassan El-Solh
Journal: Blood (2011)
The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan
Authors: Maria Gkotzamanidou, Evangelos Terpos, Nikhil C. Munshi, Vassilis L. Souliotis, Meletios A. Dimopoulos
Journal: Blood (2015)
Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991
Authors: Yousif Matloub, Bruce C. Bostrom, Stephen P. Hunger, Anne L Angiolillo, Catherine Cole, Blythe Thomson, Meenakshi Devidas, Nyla A. Heerema, Mei K La, Patrick J. Buckley, William L. Carroll, Naomi Winick, Harland Sather, James B Nachman, Paul S. Gaynon
Journal: Blood (2008)
Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.
Authors: Franck Emmanuel Nicolini, Dong-Wook Kim, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, Zhixiang Shen, Saengsuree Jootar, Graeme Smith, Carmino Antonio De Souza, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, Tomasz Szczudlo, Myriam Berton, Jim Wang, Christine Bieri, Philipp D. le Coutre
Journal: Blood (2009)